In the Claims:

Please replace claims 1, 9, 17, 18, 25 and 29-30 with the re-written forms thereof presented herewith. For the Examiner's convenience, a complete set of the pending claims is provided, with each claim labeled as appropriate as "Currently amended" or "Original".

A1

1. (Currently amended) A method for treating hyperplasia in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising drug ~~and~~ coated with a protein.

2. (Original) A method according to claim 1 wherein said drug is in nanoparticle form and is dispersed in said protein.

3. (Original) A method according to claim 1 wherein said hyperplasia occurs in blood vessel neointima.

4. (Original) A method according to claim 1 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

5. (Original) A method according to claim 4 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

6. (Original) A method according to claim 1 wherein said composition is administered systemically.

7. (Original) A method according to claim 6 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

8. (Original) A method according to claim 1 wherein said composition is administ red bef re, during or after the occurrence of said hyperplasia.

A2

9. (Currently amended) A method for reducing the intimal hyperplasia associated with vascular interventional procedure(s) in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising at least one drug ~~and~~ coated with a protein.

10. (Original) A method according to claim 9 wherein said procedure comprises angioplasty, stenting or atherectomy.

11. (Original) A method according to claim 9 wherein said composition is administered before, during or after the vascular interventional procedure.

12. (Original) A method according to claim 9 wherein said composition is administered at the time of the vascular interventional procedure.

13. (Original) A method according to claim 9 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

14. (Original) A method according to claim 13 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

15. (Original) A method according to claim 9 wherein said composition is administered systemically.

16. (Original) A method according to claim 9 wherein said composition is administered by deployment of a stent containing said at least one drug coated thereon.

A3

17. (Currently amended) A method to reduce proliferation and cell migration in a subject undergoing a vascular interventional procedure, said method comprising systemically administering a formulation comprising a drug that inhibits proliferation and

A3 cont. cell migration, and a biocompatibl protein to said subject before, during r after said procedure, wherein said drug is coated with said protein.

18. (Currently amended) A composition [for treatment of hyperplasia,] said composition comprising at least one drug ~~and~~ coated with a protein.

19. (Original) A composition according to claim 18 wherein said at least one drug is in nanoparticle form and is dispersed in said protein.

20. (Original) A composition according to claim 18 wherein said hyperplasia occurs in blood vessel neointima.

21. (Original) A composition according to claim 18 wherein said drug is a taxane or analog or homolog thereof, an epothilone or analog or homolog thereof, or a rapamycin or analog or homolog thereof.

22. (Original) A composition according to claim 21 wherein said taxane is paclitaxel.

23. (Original) A composition according to claim 18 wherein said composition is suitable for systemic administration.

24. (Original) A composition according to claim 23 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

A4 25. (Currently amended) A composition for reducing neointimal hyperplasia associated with vascular interventional procedure(s), said composition comprising at least one drug ~~and~~ coated with a protein.

26. (Original) A composition according t claim 25 wherein said procedure is angioplasty, stenting or atherectomy.

27. (Original) A composition according to claim 25 wherein said composition is suitable for systemic administration.

28. (Original) A composition according to claim 27 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

A5

29. (Currently amended) A method to reduce the toxicity of a drug that inhibits proliferation and migration of cells, said method comprising combining said drug with a biocompatible protein, wherein said drug is coated with said protein.

30. (Currently amended) A pharmaceutical formulation with reduced toxicity, said formulation comprising a drug that inhibits proliferation and cell migration, ~~and~~ coated with a biocompatible protein.